Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Class Action - March, 2006
25 articles
- In Paxil Fraud Scheme, Glaxo Pays The Price
- Court Battle Looms Over Credit Card "Hidden Tax"
- Judge Takes Air Out Of Tire Lawsuit
- AOL Time Warner Bombarded By Class Action Claims
- H&R Block Hit With Class Action Suit
- Google Antitrust Case Challenges "Monopoly Abuse"
- Air Cargo Surcharges: Global Scheme or Coincidence?
- Nortel To Settle Class Action Suits For $2.7B
- National Stock Exchanges To Settle Class Action For $43M
- Bausch & Lomb Faces Class Action Suit
- Icahn, Creditors Square Off Over Legal Fees
- Suit Claims Micron Engaged In Price-Fixing Scheme
- Class Action Suit Filed Against Global Construction Firm
- Leadis Technology Off the Hook In Class Action
- SEC Drops Pixar Probe, Class Action Continues
- Nanotechnology Maker Hit With Class Action Lawsuit
- Lumber Companies Allege Strand Board Conspiracy
- Eaton Vance Offers $10.5M To End Class Action
- Textron Agrees To Settle Class Action For $7M
- De Beers Still Plagued By Antitrust Charges
- Class Action Suit Against Marsh & McLennan Dismissed
- CMS To Pay $28M To Employees To Settle Suit
- Alza Hit With Class Action Lawsuit Over Ditropan XL
- GB Holdings Seeks Funds For Icahn's Defense
- AstraZeneca Hit Again With Antitrust Charges